Navigation Links
Despite Dramatic Changes, the Crohn's Disease Drug Market Will Experience Only Moderate Growth Through 2019
Date:9/29/2010

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic agents will outpace the decline in sales of older, established agents, which face increasing generics competition and declining use.

The Pharmacor 2010 findings from the topic entitled Crohn's Disease reveal that sales of biologic agents to treat the disease are concentrated as tumor necrosis factor-alpha (TNF-alpha) inhibitors -- namely Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira -- dominated the Crohn's disease market in 2009, capturing just over three-quarters of major-market sales. Owing to increasing physician familiarity with these agents and continuing emergence of favorable postmarketing clinical trial data, sales of TNF-alpha inhibitors will continue to grow, reaching approximately $2.8 billion in 2019.

The Pharmacor 2010 findings also reveal that the 2008 U.S. launches of Biogen Idec/Elan's Tysabri (a cell adhesion molecule inhibitor) and UCB/Otsuka's TNF-alpha inhibitor Cimzia had a negligible impact on the Crohn's disease market. Through 2019, both agents will continue to be relegated to second- or later-line biological therapy, behind Remicade and Humira.

"In 2009, sales of maintenance therapies for Crohn's disease greatly exceeded sales of acute therapies," said Decision Resources Analyst Kathryn Benton. "We expect growth in the market will be largely attributable to increasing sales of maintenance therapies and that sales of acute therapies will remain essentially flat through 2019. However, no current therapy is completely effective in maintaining remission of Crohn's disease and, as a result, significant opportunity remains for more-effective emerging therapies in the maintenance space."

Beginning in 2013, several therapies with novel mechanisms of action are expected to launch for Crohn's disease, including Millennium Pharmaceuticals' vedolizumab, Centocor Ortho Biotech/Janssen-Cilag's Stelara, Abbott's briakinumab and ChemoCentryx/GlaxoSmithKline's Traficet-EN.

"However, we forecast that none of these agents will rival the efficacy or the market share of the TNF-alpha inhibitors," Ms. Benton said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
2. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
3. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
4. UBM Japan Pharma Events Grow Despite Air Travel Disruptions
5. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
6. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
7. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
8. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
11. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com today ... Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: AGRX ... turned somewhat lower in late trade on Friday, January 20 ... about 0.3%, while shares of health care companies in the ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
Breaking Medicine Technology:
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... gynecological care and gynecological services for women of all ages. The ... a wide variety of reproductive services from routine health screenings to diagnosing and ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating ... of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the ... years, a preacher for over nineteen, a pastor for over fifteen years. He is ...
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
Breaking Medicine News(10 mins):